Sep 1, 2008
This Podcast for the Neurology Journal begins with Dr. John H. Noseworthy, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan and Dr. Myla Goldman interview Dr. Douglas Goodin about his paper on the use of natalizumab (tysabri) for treatment of multiple sclerosis. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week. The podcast concludes with Dr. Alexandra Degenhardt interviewing Dr. Neil Lava about practical aspects of natalizumab administration for the Lesson of the Week segment. The participants had nothing to disclose except for Dr. Goodin and Dr. Lava.Dr. Goodin has received honoraria for lectures or as a consultant (directly or indirectly) from Teva Neuroscience, Biogen/Idec, Merck-Serono, Bayer-Schering Healthcare and Berlex Laboratories. Dr. Goodin has received research support from Biogen-Idec, Bayer-Schering and Novartis. Dr. Lava received grants for research in the Sentinel Study.